The relevant distinction between "progression" in ovarian cancer drug trials and the clinical decision to change therapy.
我要评论
本期排行
- Intra-arterial chemotherapy fo...
- New data on BRCA mutations and...
- Radiofrequency ablation as an ...
- Prognostic model for survival ...
- Overexpression of receptor tyr...
- Short duration of sleep increa...
- Low triglyceride and nonuse of...
- The relevant distinction betwe...
- Marijuana use and testicular g...
- Glypican-3 protein expression ...
共0条评论